vs
Side-by-side financial comparison of CENTERSPACE (CSR) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.
CENTERSPACE is the larger business by last-quarter revenue ($65.1M vs $37.2M, roughly 1.7× Organogenesis Holdings Inc.). On growth, CENTERSPACE posted the faster year-over-year revenue change (-3.0% vs -57.1%). Over the past eight quarters, CENTERSPACE's revenue compounded faster (0.0% CAGR vs -46.5%).
Centerspace is a real estate investment company specializing in the ownership, operation, and development of high-quality multifamily residential properties. Its core operating markets cover the U.S. Midwest and Mountain West regions, serving diverse renter segments with both affordable and premium housing options, while focusing on tenant experience and long-term asset value growth.
Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.
CSR vs ORGO — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $65.1M | $37.2M |
| Net Profit | $-15.0M | — |
| Gross Margin | — | 30.8% |
| Operating Margin | — | -185.1% |
| Net Margin | -23.0% | — |
| Revenue YoY | -3.0% | -57.1% |
| Net Profit YoY | -258.1% | — |
| EPS (diluted) | $-0.49 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $65.1M | $37.2M | ||
| Q4 25 | $66.6M | $225.6M | ||
| Q3 25 | $71.4M | $150.9M | ||
| Q2 25 | $68.5M | $101.0M | ||
| Q1 25 | $67.1M | $86.7M | ||
| Q4 24 | $66.4M | $126.7M | ||
| Q3 24 | $65.0M | $115.2M | ||
| Q2 24 | $65.0M | $130.2M |
| Q1 26 | $-15.0M | — | ||
| Q4 25 | $-18.4M | $43.7M | ||
| Q3 25 | $53.8M | $21.6M | ||
| Q2 25 | $-14.5M | $-9.4M | ||
| Q1 25 | $-3.7M | $-18.8M | ||
| Q4 24 | $-5.1M | $7.7M | ||
| Q3 24 | $-1.0M | $12.3M | ||
| Q2 24 | $-1.3M | $-17.0M |
| Q1 26 | — | 30.8% | ||
| Q4 25 | 96.5% | — | ||
| Q3 25 | 96.5% | — | ||
| Q2 25 | 96.5% | — | ||
| Q1 25 | 96.4% | 72.6% | ||
| Q4 24 | 96.5% | 75.5% | ||
| Q3 24 | 96.6% | 76.7% | ||
| Q2 24 | 96.6% | 77.6% |
| Q1 26 | — | -185.1% | ||
| Q4 25 | -15.9% | 28.1% | ||
| Q3 25 | — | 13.7% | ||
| Q2 25 | -9.9% | -12.5% | ||
| Q1 25 | 7.1% | -30.9% | ||
| Q4 24 | 4.3% | 8.1% | ||
| Q3 24 | 9.8% | 5.4% | ||
| Q2 24 | 11.1% | -10.7% |
| Q1 26 | -23.0% | — | ||
| Q4 25 | -27.7% | 19.4% | ||
| Q3 25 | 75.3% | 14.3% | ||
| Q2 25 | -21.2% | -9.3% | ||
| Q1 25 | -5.6% | -21.7% | ||
| Q4 24 | -7.6% | 6.1% | ||
| Q3 24 | -1.6% | 10.7% | ||
| Q2 24 | -2.0% | -13.1% |
| Q1 26 | $-0.49 | — | ||
| Q4 25 | $-1.08 | $0.31 | ||
| Q3 25 | $3.19 | $0.11 | ||
| Q2 25 | $-0.87 | $-0.10 | ||
| Q1 25 | $-0.22 | $-0.17 | ||
| Q4 24 | $-0.31 | $0.05 | ||
| Q3 24 | $-0.40 | $0.09 | ||
| Q2 24 | $-0.19 | $-0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $7.6M | $91.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $695.0M | — |
| Total Assets | $1.9B | $520.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $7.6M | $91.4M | ||
| Q4 25 | $12.8M | $93.7M | ||
| Q3 25 | $12.9M | $63.7M | ||
| Q2 25 | $12.4M | $73.1M | ||
| Q1 25 | $11.9M | $110.0M | ||
| Q4 24 | $12.0M | $135.6M | ||
| Q3 24 | $14.5M | $94.3M | ||
| Q2 24 | $14.3M | $89.9M |
| Q1 26 | — | — | ||
| Q4 25 | $1.0B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $955.5M | — | ||
| Q4 24 | $955.4M | — | ||
| Q3 24 | $921.3M | $62.3M | ||
| Q2 24 | $931.7M | $63.8M |
| Q1 26 | $695.0M | — | ||
| Q4 25 | $719.2M | $300.1M | ||
| Q3 25 | $748.6M | $255.1M | ||
| Q2 25 | $710.1M | $233.2M | ||
| Q1 25 | $636.8M | $242.9M | ||
| Q4 24 | $752.0M | $262.9M | ||
| Q3 24 | $672.5M | $278.5M | ||
| Q2 24 | $680.7M | $263.5M |
| Q1 26 | $1.9B | $520.0M | ||
| Q4 25 | $1.9B | $598.7M | ||
| Q3 25 | $2.1B | $509.8M | ||
| Q2 25 | $2.0B | $461.1M | ||
| Q1 25 | $1.9B | $467.4M | ||
| Q4 24 | $1.9B | $497.9M | ||
| Q3 24 | $1.9B | $446.3M | ||
| Q2 24 | $1.9B | $443.2M |
| Q1 26 | — | — | ||
| Q4 25 | 1.42× | — | ||
| Q3 25 | 1.53× | — | ||
| Q2 25 | 1.57× | — | ||
| Q1 25 | 1.50× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.37× | 0.22× | ||
| Q2 24 | 1.37× | 0.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
